title: Bortezomib, lenalidomide and dexamethasone (VRD) combination as salvage therapy in refractory angioimmunoblastic T cell lymphoma.
authors.forename: Driss
authors.initials: D
authors.lastname: Chaoui
authors.forename: Sonia
authors.initials: S
authors.lastname: Bouallegue
authors.forename: Nina
authors.initials: N
authors.lastname: Arakelyan
authors.forename: Philippe
authors.initials: P
authors.lastname: Genet
authors.forename: Ahmad
authors.initials: A
authors.lastname: Aljijakli
authors.forename: Laurent
authors.initials: L
authors.lastname: Sutton
mesh_terms: D000368:Aged; D000369:Aged, 80 and over; D001897:Boronic Acids / Q000627:therapeutic use*; D000069286:Bortezomib; D003907:Dexamethasone / Q000627:therapeutic use*; D004359:Drug Therapy, Combination / Q000379:methods; D005260:Female; D006801:Humans; D007119:Immunoblastic Lymphadenopathy / Q000188:drug therapy; D000077269:Lenalidomide; D016399:Lymphoma, T-Cell / Q000188:drug therapy*; D011719:Pyrazines / Q000627:therapeutic use*; D016879:Salvage Therapy / Q000379:methods*; D013792:Thalidomide / Q000031:analogs & derivatives* / Q000627:therapeutic use; D014055:Tomography, Emission-Computed
chemical_list: D001897:Boronic Acids; D011719:Pyrazines; D013792:Thalidomide; D000069286:Bortezomib; D003907:Dexamethasone; D000077269:Lenalidomide